Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-07

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aim to evaluate whether some substances produced by muscle or adipose tissue may play a role in the course of the disease by interfering with the effectiveness of therapies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.

NCT02968979

Non-small Cell Lung Cancer Cachexia

COMPLETED

Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer

NCT05212285

Sarcopenia Non Small Cell Lung Cancer Malnutrition

COMPLETED

Cachexia in NSCLC Patients: Diagnosis, Characterization, Prognosis, Functional and Skeletal Muscle Implications

NCT03960034

NSCLC Stage IV

COMPLETED

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

NCT06073431

Advanced Colorectal Carcinoma Advanced Lung Non-Small Cell Carcinoma Advanced Pancreatic Adenocarcinoma +6 more

RECRUITING

Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer

NCT01885754

Non-Small-cell Lung Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is aimed at patients with NSCLC in whom plasma levels of particular biomarkers will be studied before and after treatment with chemotherapy and immunotherapy or immunotherapy alone.

In particular, the plasma levels of GDF15, FGF21, HN, Activin molecules and microRNAs involved in inflammatory processes, called inflammamiR, in particular of microRNA146, 126, 21, 188, 155, will be studied.

Assessments of cellular markers of leukocyte aging will also be performed (determination of telomere length is a widely used measure of biological aging)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with NSCLC in advanced stage (IIIB, IV)
* Patients eligible for the treatment with single-agent immunotherapy (Pembrolizumab), or a chemo-immunotherapy combination among the approved ones for I line
* Obtainment of the informations related to medical history and the possibility to have an adequate follow up
* Obtainment of the informed consent
* Age ≥ 18 years

Exclusion Criteria

* Patients with psychiatric alterations, neurological diseases or other condistions that could not allow adhesion to study protocol and the obtainment of the ICF

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No